Jefferies Financial Group Inc. Makes New $5.93 Million Investment in Biogen Inc. $BIIB

Jefferies Financial Group Inc. acquired a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, HoldingsChannel.com reports. The fund acquired 27,463 shares of the biotechnology company’s stock, valued at approximately $5,934,000.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Biogen in the 2nd quarter valued at $3,453,878,000. Primecap Management Co. CA acquired a new position in Biogen during the 2nd quarter worth $3,274,304,000. Geode Capital Management LLC boosted its stake in Biogen by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after purchasing an additional 130,618 shares during the period. Norges Bank bought a new stake in shares of Biogen in the fourth quarter valued at approximately $464,408,000. Finally, Invesco Ltd. grew its position in Biogen by 4.2% in the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after purchasing an additional 98,001 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. TD Cowen raised their target price on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Oppenheimer restated an “outperform” rating and issued a $300.00 target price on shares of Biogen in a research note on Wednesday, July 29th. Finally, Weiss Ratings cut shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $227.79.

Biogen Price Performance

Shares of BIIB stock opened at $218.50 on Friday. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.85. The firm’s 50 day moving average is $207.81 and its 200-day moving average is $195.68. The firm has a market capitalization of $32.28 billion, a price-to-earnings ratio of 38.67, a PEG ratio of 6.90 and a beta of 0.17. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter last year, the business posted $5.47 earnings per share. Biogen’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts forecast that Biogen Inc. will post 12.39 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.